Table 1. Patient Characteristics and Response Summary.

Cy indicates cyclophosphamide; Vinc, vincristine; Pred, prednisone; Etop, Etoposide; Peg, pegylated asparaginase; Mito, mitoxantrone; CR1, first complete remission; MRD, minimal residual disease as assessed by deep sequencing (see Supplemental Data); Allo-SCT, allogeneic stem cell transplant. All patients were treated with cyclophosphamide before T cell infusion, either 1.5 gm/m² (MSK-ALL04, MSKALL05, MSK-ALL06) or 3.0 gm/m² (MSK-ALL01, MSK-ALL03).

Patient ID*	Age	FISH/Cyto genetics	Initial therapy	Duration of CR1	Salvage therapy	Disease response to Salvage therapy**	Disease Response	Steroids	Outcome
MSK- ALL01	66	Normal karyotype	Mito/Cy → Vinc/Pred → Cy→ Etop/Cy	27 weeks	Vinc/Pred/Peg	MRD+	MRD−	N	Allo-SCT
MSK- ALL03	56	Normal karyotype	HyperCVAD	45 weeks	Inotuzumab ozogamicin → Vinc/Pred/Peg	MRD−	MRD−	N	Allo-SCT
MSK- ALL04	59	t(9;11), 9p21 deletion	ECOG2993(24)	5 weeks	Vinc/Pred	Refractory disease, 63% blasts in BM	MRD−	Y	Ineligible for Allo-SCT, relapse 90 days
MSK- ALL05***	58	9p21 deletion	ECOG2993	28 weeks	HIDAC/Mito	Refractory disease, 70% blasts in BM	MRD−	Y	Allo-SCT
MSK- ALL06	23	Normal karyotype	NYII ref (25)	34 months	Modified NYII Consolidation I ref (25)	MRD+	MRD−	N	Allo-SCT

^*MSK-ALL02 patient was removed from the study prior to the planned T cell infusion because they deferred T cell infusion for an allo-SCT.

^**Disease status within 1 week of infusion with CD19-targeted T cells

^***This patient’s T cells were harvested while in remission. All other patients listed had their T cells harvested while they had relapsed disease.